NovoCure Ltd’s board lost Timothy Scannell effective September 2, 2026, when his director seat was vacated under the Articles of Association. The company said the retirement did not stem from disagreement with management or NovoCure, leaving investors with a stated governance change without an associated dispute.

Key Highlights

  • NovoCure said Timothy Scannell’s retirement was not caused by disagreement with the company or its management.
  • Chief Financial Officer Christoph Brackmann signed the report on NovoCure’s behalf on September 9, 2026.
  • Scannell was identified as a current NovoCure director before his board departure.

NovoCure Ltd (NASDAQ: NVCR) lost Timothy Scannell from its Board effective September 2, 2026, when his seat was vacated under the company’s Articles of Association. The retirement was not attributed to any disagreement with NovoCure or its management.

Board Departure Takes Effect September 2

Scannell was a current director before the change. NovoCure characterized his board service as distinguished, while confirming that the retirement did not result from a conflict with the company or its management. Chief Financial Officer Christoph Brackmann signed on behalf of NovoCure on September 9, 2026. The change leaves the director seat formally vacated as of September 2.